U.S. Markets closed

Clovis Oncology, Inc. (CLVS)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
95.00-1.78 (-1.84%)
At close: 4:00PM EDT
People also watch
TSROPBYIKITEBLUESRPT
Full screen
Previous Close96.78
Open96.50
Bid90.23 x 100
Ask95.59 x 100
Day's Range92.33 - 96.70
52 Week Range11.57 - 96.92
Volume2,536,243
Avg. Volume1,959,751
Market Cap4.58B
Beta1.86
PE Ratio (TTM)-11.69
EPS (TTM)-8.13
Earnings DateAug 7, 2017 - Aug 11, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est92.73
Trade prices are not sourced from all markets
  • 3 Growth Stocks for Bright Investors
    Motley Foolyesterday

    3 Growth Stocks for Bright Investors

    For bright investors in search of some new ideas here are three stocks worth a good look.

  • Zacksyesterday

    Healthcare ETF (IYH) Hits New 52-Week High

    This healthcare ETF hit a new 52-week high. Are more gains in store for this ETF?

  • American City Business Journals2 days ago

    Clovis Oncology commencing $250 million stock offering

    One day after announcing good results of a trial of its ovarian cancer drug rucaparib, Clovis Oncology Inc. said it's commencing a $250 million public offering of its stock. Clovis will use the money for sales and marketing of its drug rucaparib, both in the United States and, if approved by the European Medicines Agency, in Europe, as well as to fund the compay's drug development programs, general and administrative expenses, and possible acquisitions or licensing of of new drug candidates, the Boulder biotech said in a statement. Reaction to the stock offering is positive enough that the investment banks underwriting it exercised their option to purchase an additional 511,363 shares, Clovis said Thursday.